Mounjaro Outperforms Other GLP-1 Drugs in Early Type 2 Diabetes, New Study Finds

A new clinical trial suggests that people newly diagnosed with type 2 diabetes may do significantly better on Eli Lilly’s Mounjaro than on other drugs in the same class. This matters especially when standard first-line treatment isn’t doing enough. The findings appear in the Annals of Internal Medicine.

The trial, called SURPASS-EARLY, followed nearly 800 adults with type 2 diabetes. All had received a diagnosis within the past four years. All were already taking metformin alongside diet and exercise guidance. Yet their blood sugar remained uncontrolled. Researchers then had them add either tirzepatide or another medication to their existing regimen.

Most patients in the comparison group took semaglutide. Novo Nordisk sells that drug as Ozempic or Rybelsus for diabetes. Others took Lilly’s own Trulicity (dulaglutide). Both target the GLP-1 receptor and carry solid track records in type 2 diabetes care.

After two years, tirzepatide pulled ahead on nearly every measure. Patients on tirzepatide cut their hemoglobin A1c more than the control group did. They also lost more weight and trimmed more off their waist circumference.

The normoglycemia results stood out most. Around 60% of tirzepatide patients reached normal blood sugar levels by year two. Only 24% in the control group hit that mark. Sustained normal blood glucose matters because it lowers the long-term risk of kidney disease, nerve damage, and heart problems.

Tirzepatide’s dual mechanism likely explains the gap. Most GLP-1 drugs activate only one receptor. Tirzepatide hits two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). That broader action boosts insulin secretion, curbs appetite, and drives greater weight loss than single-pathway agents can achieve.

The study authors argued for moving to tirzepatide sooner, rather than cycling through other GLP-1 options first. That thinking runs counter to the usual step-by-step escalation approach many clinicians follow today.

A few caveats deserve attention. Eli Lilly funded the trial. The control group took several different drugs rather than a single comparator. These factors add complexity when weighing the results. Industry funding always warrants scrutiny, and readers should factor that in.

Even so, tirzepatide’s edge held firm across glycemic control, weight, and waist circumference over a full two years. That consistency strengthens the finding. FDA approves Mounjaro for type 2 diabetes in adults. Patients need a prescription to access it.